Pluristem Therapeutics Inc - Articles and news items

Pluristem advances towards multinational Phase III trial of PLX-PAD

Industry news / 28 July 2016 / Pluristem Therapeutics Inc.

Pluristem Therapeutics Inc. has today announced its intentions to conduct a Phase III trial assessing its PLX-PAD cells in recovery following surgery for femoral neck fracture, which is the most common form of hip fracture…

Pluristem contracts CRO for Phase I trial of PLX-R18

Industry news / 12 July 2016 / Victoria White, Digital Content Producer

The Phase I trial will evaluate the safety of intramuscular injections of PLX-R18 cells in 30 patients with incomplete haematopoietic recovery…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+